Peptide blend · BPC-157 + TB-500 + GHK-Cu
Is GLOW legal?
The short answer
No. GLOW is not legal to sell or compound for human use anywhere Peptlas tracks.
GLOW is a seller’s name for a premixed vial of BPC-157, TB-500 and GHK-Cu. The name is a market label, not a regulated product, so amounts, ratios and purity vary by seller.
In the U.S., none of its 3 ingredients is on the FDA’s 503A bulks list, so no pharmacy can lawfully compound GLOW, and selling it for people to inject is selling an unapproved drug, whatever the “research use only” label says. The FDA’s advisory committee recommended BPC-157 and TB-500 for that list in July 2026; the vote is advisory, and the FDA has not acted.
Elsewhere the strictest ingredient decides: GLOW is restricted in Australia, the UK, the EU, Canada and Brazil, and banned in sport, because WADA prohibits BPC-157 and TB-500.
Worked out from its 3 ingredient entries · oldest check Sep 22, 2026 (ET) · every status links to its primary source
What’s in it
- BPC-157In limboPCAC recommended listing (8-6, Jul 23, 2026) - advisory only; still not on the 503A list
- TB-500 (Thymosin Beta-4)In limboPCAC recommended listing (8-6, Jul 23, 2026) - advisory only; still not on the 503A list
- GHK-CuIn limboInjectable removed from Category 2, not on the 503A list; PCAC review expected before end of Feb 2027
U.S. status shown. Peptlas doesn’t link sellers, and no blend is an FDA-approved product. What “legal” means for selling, compounding and importing is on are peptides legal?
Place by place
A blend can never be more legal than its least legal ingredient, so each place takes its strictest one.
| Place | GLOW | Set by |
|---|---|---|
| United States (FDA) | In limbo | BPC-157 and TB-500: Not on the 503A Bulks List. PCAC recommended adding it on Jul 23, 2026 (8-6, 1 abstention); the recommendation is advisory and the FDA has not acted.GHK-Cu: Topical route ≈ Category 1; injectable route removed from Category 2, not on the 503A list; PCAC review expected before end of Feb 2027. |
| Australia (TGA) | Restricted | BPC-157: Reported as Schedule 4 (prescription-only) under the Poisons Standard.TB-500: Thymosin beta-4 treated as Schedule 4 (prescription-only) under the Poisons Standard. |
| United Kingdom (MHRA) | Restricted | BPC-157 and TB-500: No UK marketing authorisation; supply for human use treated as an unlicensed medicine.GHK-Cu: No UK marketing authorisation; supply as a medicine is unlicensed, though copper tripeptide-1 remains a permitted cosmetic ingredient under GB cosmetics law. |
| European Union (EMA) | Restricted | BPC-157, TB-500 and GHK-Cu: No EU marketing authorisation; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Canada (Health Canada) | Restricted | BPC-157: Not an authorized drug; Health Canada’s April 2026 advisory names BPC-157 among unauthorized injectable peptides and states such products are illegal to sell in Canada.TB-500: Not authorized for sale; Health Canada has seized TB-500 among unauthorized injectable peptides and states selling unauthorized drugs is illegal in Canada.GHK-Cu: Not in the Drug Product Database; Health Canada recalled GHK-Cu powder as an unauthorized active pharmaceutical ingredient in May 2026. |
| Sport (WADA) | Restricted | BPC-157: Prohibited at all times under category S0 (non-approved substances). Unchanged on the 2027 List (published Sep 21, 2026; in force Jan 1, 2027).TB-500: Prohibited at all times as a growth factor / non-approved substance. Unchanged on the 2027 List (published Sep 21, 2026; in force Jan 1, 2027). |
| Brazil (ANVISA) | Restricted | BPC-157 and TB-500: Sem registro na ANVISA: uso ilegalGHK-Cu: Injetável sem registro: uso ilegal |
Each status is the ingredient’s own, from its entry. The full grid of restricted and other statuses is on peptide legal status by country.
Regulators that named it
- Oct 6, 2026Brazil (ANVISA). Resolution RE 3.947/2026 banned the sale, manufacture, advertising and use of “Glow GHK-CU 70 mg” (Alluvi Healthcare), sold online, and ordered it seized. Source
What could change it
- The FDA’s response to the July 2026 committee votes on BPC-157 and TB-500: no date announced.
- GHK-Cu: Second PCAC meeting on peptides, incl. GHK-Cu - expected before end of Feb 2027, no date published.
Even then, GLOW could only be compounded once every ingredient is on the list, and only on a prescription for one patient. Get an email when any ingredient’s status changes: each ingredient page has the signup.
Asked and answered
- Is GLOW legal?
- No. GLOW is not legal to sell or compound for human use anywhere Peptlas tracks. In the U.S., none of its 3 ingredients is on the FDA’s 503A bulks list, so no pharmacy can lawfully compound GLOW, and selling it for people to inject is selling an unapproved drug, whatever the “research use only” label says. The FDA’s advisory committee recommended BPC-157 and TB-500 for that list in July 2026; the vote is advisory, and the FDA has not acted.
- Can a pharmacy compound GLOW?
- Not legally in the U.S. A compounded blend needs every ingredient to be eligible, and BPC-157, TB-500 and GHK-Cu are not on the FDA’s 503A bulks list.
- Is GLOW banned in sport?
- Yes. WADA prohibits BPC-157 and TB-500, so a blend containing them is banned for tested athletes.
- What is the difference between KLOW, GLOW and the Wolverine stack?
- They share ingredients: KLOW is BPC-157, TB-500, GHK-Cu and KPV; GLOW is BPC-157, TB-500 and GHK-Cu; the Wolverine stack is BPC-157 and TB-500.
Sources
- Superpower - GLOW peptide blend, and how KLOW differs (updated Sep 28, 2026) ”GLOW is a product name for an injectable blend of three peptides: GHK-Cu, BPC-157, and TB-500.”
- Resident - The GLOW peptide blend: why everyone is searching for it (Sep 25, 2026) A typical vial combines GHK-Cu, BPC-157 and TB-500.
These confirm what the blend contains. Every status comes from the ingredient’s own entry, which lists its primary sources.